The FDA assessed the protection and success of atidarsagene autotemcel according to knowledge from 37 small children who received atidarsagene autotemcel in two single-arm, open-label scientific trials and in an expanded access plan.[7] Children who obtained remedy with atidarsagene autotemcel have been as compared to untreated kids (organic backgr… Read More